Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial (vol 376, pg 705, 2010)

被引：0
|
作者：
Kwo, P. Y.
Lawitz, E. J.
McCone, J.
机构：
来源：
LANCET | 2010年 / 376卷 / 9748期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1224 / 1224
页数：1
相关论文
共 50 条
  • [31] Camel Milk with Pegylated Interferon Alfa-2a and Ribavirin for Treatment-Naive Chronic Hepatitis C Genotype 2/3: An Open-Label, Randomized Controlled Trial
    Hosseini, Seyyd Musa al-Reza
    Zibaee, Said
    Yousefi, Mahdi
    Taghipour, Ali
    Ghanaei, Omid
    Noras, Mohammadreza
    IRANIAN RED CRESCENT MEDICAL JOURNAL, 2017, 19 (09)
  • [32] SAFETY AND EFFICACY OF MK-5172 PLUS PEGINTERFERON ALFA-2b AND RIBAVIRIN (PR) IN CIRRHOTIC AND NON-CIRRHOTIC TREATMENT-NAIVE PATIENTS WITH HEPATITIS C VIRUS (HCV) GENOTYPE (G)1 INFECTION
    Hezode, C.
    Bruno, S.
    Jacobson, I.
    Serfaty, L.
    Kwo, P.
    Zhou, A.
    Gilbert, C.
    Hwang, P.
    Wahl, J.
    Robertson, M. N.
    Mobashery, N.
    JOURNAL OF HEPATOLOGY, 2014, 60 (01) : S500 - S500
  • [33] COMBINATION THERAPY OF TREATMENT-NAIVE AND NONRESPONDER PATIENTS WITH HCV GENOTYPE 1 INFECTION WITH BMS-790052, AN NS5A REPLICATION COMPLEX INHIBITOR, IN COMBINATION WITH PEGINTERFERON ALFA-2A AND RIBAVIRIN
    Izumi, Namiki
    Asahina, Yasuhiro
    Yokosuka, Osamu
    Imazeki, Fumio
    Kawada, Norifumi
    Tamori, Akihiro
    Osaki, Yukio
    Kimura, Toru
    Yamamoto, Kazuhide
    Takaki, Akinobu
    Sata, Michio
    Ide, Tatsuya
    Ishikawa, Hiroki
    Ueki, Tomoko
    Yang, Rong
    McPhee, Fiona
    Hughes, Eric A.
    HEPATOLOGY, 2011, 54 : 1439A - 1440A
  • [34] Ledipasvir and sofosbuvir plus ribavirin in patients with genotype 1 or 4 hepatitis C virus infection and advanced liver disease: a multicentre, open-label, randomised, phase 2 trial
    Manns, Michael
    Samuel, Didier
    Gane, Edward J.
    Mutimer, David
    McCaughan, Geoff
    Buti, Maria
    Prieto, Martin
    Luis Calleja, Jose
    Peck-Radosavljevic, Markus
    Mullhaupt, Beat
    Agarwal, Kosh
    Angus, Peter
    Yoshida, Eric M.
    Colombo, Massimo
    Rizzetto, Mario
    Dvory-Sobol, Hadas
    Denning, Jill
    Arterburn, Sarah
    Pang, Phillip S.
    Brainard, Diana
    McHutchison, John G.
    Dufour, Jean-Francois
    Van Vlierberghe, Hans
    van Hoek, Bart
    Forns, Xavier
    LANCET INFECTIOUS DISEASES, 2016, 16 (06): : 685 - 697
  • [35] Ledipasvir and sofosbuvir fixed-dose combination with and without ribavirin for 12 weeks in treatment-naive and previously treated Japanese patients with genotype 1 hepatitis C: an open-label, randomised, phase 3 trial
    Mizokami, Masashi
    Yokosuka, Osamu
    Takehara, Tetsuo
    Sakamoto, Naoya
    Korenaga, Masaaki
    Mochizuki, Hitoshi
    Nakane, Kunio
    Enomoto, Hirayuki
    Ikeda, Fusao
    Yanase, Mikio
    Toyoda, Hidenori
    Genda, Takuya
    Umemura, Takeji
    Yatsuhashi, Hiroshi
    Ide, Tatsuya
    Toda, Nobuo
    Nirei, Kazushige
    Ueno, Yoshiyuki
    Nishigaki, Yoichi
    Betular, Juan
    Gao, Bing
    Ishizaki, Akinobu
    Omote, Masa
    Mo, Hongmei
    Garrison, Kim
    Pang, Phillip S.
    Knox, Steven J.
    Symonds, William T.
    McHutchison, John G.
    Izumi, Namiki
    Omata, Masao
    LANCET INFECTIOUS DISEASES, 2015, 15 (06): : 645 - 653
  • [36] A pilot study of add-on oral hypoglycemic agents in treatment-naive genotype-1 chronic hepatitis C patients receiving peginterferon alfa-2b plus ribavirin
    Hsu, Ching-Sheng
    Hsu, Shih-Jer
    Lin, Hans Hsienhong
    Tseng, Tai-Chung
    Wang, Chia-Chi
    Chen, Ding-Shinn
    Kao, Jia-Horng
    JOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION, 2014, 113 (10) : 716 - 721
  • [37] Boceprevir versus placebo with pegylated interferon alfa-2b and ribavirin for treatment of hepatitis (virus genotype 1 in patients with HIV: a randomised, double-blind, controlled phase 2 trial
    Sulkowski, Mark
    Pol, Stanislas
    Mallolas, Josep
    Fainboim, Hugo
    Cooper, Curtis
    Slim, Jihad
    Rivero, Antonio
    Mak, Carmen
    Thompson, Seth
    Howe, Anita Y. M.
    Wenning, Larissa
    Sklar, Peter
    Wahl, Janice
    Greaves, Wayne
    LANCET INFECTIOUS DISEASES, 2013, 13 (07): : 597 - 605
  • [38] Vaniprevir plus peginterferon alfa-2b and ribavirin in treatment-experienced Japanese patients with hepatitis C virus genotype 1 (GT1b) infection: Phase 3 studies
    Kumada, Hiromitsu
    Mochida, Satoshi
    Suzuki, Fumitaka
    Chayama, Kazuaki
    Karino, Yoshiyasu
    Nakamura, Keisuke
    Fujimoto, Go
    Howe, Anita Y. M.
    Ludmerer, Steve W.
    Mobashery, Niloufar
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2016, 31 (10) : 1674 - 1683
  • [39] An Open-Label Trial of 12-Week Simeprevir plus Peginterferon/Ribavirin (PR) in Treatment-Naive Patients with Hepatitis C Virus (HCV) Genotype 1 (GT1)
    Asselah, Tarik
    Moreno, Christophe
    Sarrazin, Christoph
    Gschwantler, Michael
    Foster, Graham R.
    Craxi, Antonio
    Buggisch, Peter
    Ryan, Robert
    Lenz, Oliver
    Scott, Jane
    Van Dooren, Gino
    Lonjon-Domanec, Isabelle
    Schlag, Michael
    Buti, Maria
    PLOS ONE, 2016, 11 (07):
  • [40] Ledipasvir and sofosbuvir plus ribavirin in patients with genotype 1 or 4 hepatitis C virus infection and advanced liver disease: a multicentre, open-label, randomised, phase 2 trial (vol 16, pg 685, 2016)
    Manns, M.
    Samuel, D.
    Gane, E. J.
    LANCET INFECTIOUS DISEASES, 2016, 16 (06): : 636 - 636
12345